InvestorsHub Logo
Followers 84
Posts 6987
Boards Moderated 0
Alias Born 02/03/2018

Re: marjac post# 370971

Thursday, 02/17/2022 11:04:01 AM

Thursday, February 17, 2022 11:04:01 AM

Post# of 426632
Marjac, Reduce-it patents were awarded for running a high risk, high cost trial, at the expense of a lengthy go to market OPPORTUNITY. It was specifically for reasons of nonobviousness, where biomarkers were held to be insufficient proxies to claim CVD benefits, which was the impetus for burdening Amarin to run an outcomes based trial. Trial data are automatic patentable rights.

ILT
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News